Autolus Therapeutics (AUTL) Other Non-Current Liabilities (2021 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Other Non-Current Liabilities of $477000.0 for Q4 2025, up 11.97% year-on-year from $426000.0 in Q4 2024, and up 1.06% on a QoQ basis from $472000.0 in Q3 2025.
Autolus Therapeutics (AUTL) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Other Non-Current Liabilities for 5 consecutive years, with $477000.0 the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 11.97% year-over-year to $477000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $477000.0 (up 11.97% YoY) and the FY2025 annual result came in at $477000.0, up 11.97% from the prior year.
- Other Non-Current Liabilities improved to $477000.0 in Q4 2025 per AUTL's latest filing, from $472000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for AUTL reached as high as $477000.0 in Q2 2025 and fell as low as $105000.0 in Q3 2022.
- A 5-year average of $296647.1 and a median of $357000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities retreated 9.38% — and 2024, when it soared 258.77%.
- Year by year, Other Non-Current Liabilities stood at $128000.0 in 2021, then fell by 9.38% to $116000.0 in 2022, then surged by 207.76% to $357000.0 in 2023, then rose by 19.33% to $426000.0 in 2024, then grew by 11.97% to $477000.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $477000.0, $472000.0, and $477000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Autolus Therapeutics | 393.78 Mn | 93.07 Mn | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | 472,000.00 |
| Jun 30, 2025 | 477,000.00 |
| Mar 31, 2025 | 444,000.00 |
| Dec 31, 2024 | 426,000.00 |
| Sep 30, 2024 | 447,000.00 |
| Jun 30, 2024 | 415,000.00 |
| Mar 31, 2024 | 409,000.00 |
| Dec 31, 2023 | 357,000.00 |
| Sep 30, 2023 | 295,000.00 |
| Jun 30, 2023 | 122,000.00 |
| Mar 31, 2023 | 114,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | 105,000.00 |
| Jun 30, 2022 | 115,000.00 |
| Mar 31, 2022 | 124,000.00 |
| Dec 31, 2021 | 128,000.00 |